Frank M. Sands insider trades: Inhibikase Therapeutics (IKT) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Frank reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 21, 2025 | IKT | ↑ Buy | 2,068,965 | $1.45 | $3.0M | Direct | Nov 24, 2025 (3d) |
| Jul 6, 2021 | ABOS | ↑ Buy | 450,000 | $14.88 | $6.7M | Direct | Jul 8, 2021 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other IKT insiders
Open-market trades in the last 12 months
About Frank M. Sands's insider trades
Frank M. Sands is a 10% owner of Inhibikase Therapeutics (IKT). Since Jul 6, 2021, Frank has reported 2 open-market purchases worth $9.7M and no sales on SEC Form 4. In the last 12 months: 1 buy ($3.0M).
Their filings also include conversions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every IKT insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.